Business Parks & Science Centres

 
 
 

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px
Document › Details

Marinomed Biotech AG. (1/29/19). "Press Release: Marinomed Announces Strong Investor Demand and Expected Offer Price (Adhoc-News)".

Region Region Wien (state)
  Country Austria
Organisations Organisation Marinomed Biotech AG (VSE: MARI)
  Organisation 2 Vienna Stock Exchange (VSE)
Products Product Carragelose®
  Product 2 investment banking
Index term Index term Marinomed–SEVERAL: investment, 201811–201901 IPO €19.5m+€2.925m with 260k+39k new bearer shares at €75/share
Person Person Prieschl-Grassauer, Eva (Marinomed Biotechnologie GmbH 201307 CSO)
     


Marinomed Biotech AG has already received subscription orders for more than 299,000 new bearer shares (base deal incl. 15% over-allotment /Greenshoe) as part of the current IPO and listing on the Vienna Stock Exchange (the "Offering"). The transaction meets the requirements of a qualified public offer in accordance with the terms and conditions of the convertible bonds issued in 2017 that are traded on the Third Market of the Vienna Stock Exchange. The Offer Price is expected to be EUR 75 per share. No adjustment of the Conversion Price I (as defined in the terms and conditions of the convertible bonds) is therefore expected to be necessary.

The Offer Period will end today at 12.00 CET for retail investors and at 17.00 CET for institutional investors. The expected settlement date and first trading day is 1 February 2019. From this date the Marinomed shares are intended to be traded under the symbol "MARI" on the official market (prime market segment) of the Vienna Stock Exchange.


About Marinomed Biotech AG

Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the development of innovative products derived from patent protected technology platforms to treat respiratory and ophthalmic conditions. The Carragelose® platform comprises innovative patent protected products targeting viral infections of the respiratory tract. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold in more than 30 countries around the world in collaboration with international partners. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose. Further information is available at www.marinomed.com.


Enquiries:

Eva Prieschl-Grassauer, PhD
Chief Scientific Officer, Marinomed
Veterinärplatz 1, 1210 Vienna, Austria
Tel.: +43 (0)1 250 77 4460
E-mail: eva.prieschl@marinomed.com
http://www.marinomed.com

Roland Mayrl
Managing Partner, Metrum Communications
Prinz-Eugen-Straße 80/16, 1040 Vienna, Austria
Tel.: +43 (0) 1 504 69 87 331
E-mail: r.mayrl@metrum.at
http://www.metrum.at


Disclaimer

This announcement does not constitute an offer to purchase securities or solicitation of an offer to purchase securities in the United States of America, Germany, Austria or other jurisdictions. The shares (the "Shares") of Marinomed Biotech AG (the "Company") may only be sold or offered for sale after prior registration in the United States of America upon or without prior registration by virtue of an exemption from the registration requirement under the provisions of the US Securities Act of 1933, as amended. The Company does not intend to fully or partially register any offer of Shares in the United States or to make any public offering of Shares in the United States.

A public offering of securities of the Company in Austria is made solely by, and on the basis of, a prospectus (including the supplements thereto) for securities prepared and published in accordance with the provisions of the Capital Markets Act (Kapitalmarktgesetz), which was approved and published on 16 November 2018. An investment decision regarding publicly offered securities of the Company should only be made on the basis of such a prospectus. Any purchase orders relating to securities of the Company received prior to the resumption of the public offering will be rejected. The prospectus as well as the supplements thereto are available free of charge at Marinomed Biotech AG, Veterinärplatz 1, A-1210 Vienna, or on the website of Marinomed Biotech AG (https://www.marinomed.com/offering).

   
Record changed: 2019-02-01

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Marinomed Biotech AG (VSE: MARI)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px




» top